Close

Halozyme Therapeutics (HALO) Reports Removal of FDA Clinical Hold on PEGPH20 Phase 1b/2

September 18, 2014 9:20 AM EDT Send to a Friend
Halozyme Therapeutics (Nasdaq: HALO) announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login